FDA Delays Action On MedImmune's Rezield Despite Negative Panel Vote
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency may have needed more time to investigate allegations in a wrongful discharge lawsuit challenging data integrity in a motavizumab surveillance study.